Wave Life Sciences Ltd. 8-K

What Happened

• On April 15, 2026, Wave Life Sciences Ltd. (the Singapore parent, “Wave‑Singapore”) and Wave Life Sciences, Inc. (a newly formed Delaware corporation, “Wave‑Delaware”) executed an Implementation Agreement to effect a redomiciliation.
• Under the agreed Scheme of Arrangement, each issued ordinary share of Wave‑Singapore will be exchanged on a one‑for‑one basis for newly issued shares of Wave‑Delaware common stock, after shareholder and Singapore High Court approval. A preliminary proxy on Schedule 14A is expected to be filed with the SEC on April 15, 2026.

Key Details

• Date executed: April 15, 2026 (Implementation Agreement signed by Wave‑Singapore and Wave‑Delaware).
• Share exchange: 1-for-1 swap of Wave‑Singapore ordinary shares for Wave‑Delaware common stock at the scheme’s effective time.
• Approvals required: shareholder vote of Wave‑Singapore and approval by the High Court of the Republic of Singapore; other customary closing conditions and regulatory approvals.
• Communications: Wave‑Singapore issued a press release the same day; a definitive proxy statement will be mailed to shareholders and filed with the SEC.

Why It Matters

• The redomiciliation would change the group parent from a Singapore company to a Delaware corporation, which can affect corporate governance, regulatory jurisdiction and potentially tax or administrative processes.
• Completion is not automatic: it depends on shareholder and court approvals and other conditions noted in the filing, so investors should review the forthcoming definitive proxy and related SEC filings before making voting or investment decisions.